Get the Stockscreener App
45.70
3.72%
1.64
Sionna Therapeutics Inc stock is traded at $45.70, with a volume of 654.83K.
It is up +3.72% in the last 24 hours and up +11.22% over the past month.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
See More
Previous Close:
$44.06
Open:
$44.31
24h Volume:
654.83K
Relative Volume:
1.42
Market Cap:
$2.06B
Revenue:
-
Net Income/Loss:
$-85.57M
P/E Ratio:
-23.84
EPS:
-1.9166
Net Cash Flow:
$-72.14M
1W Performance:
-7.51%
1M Performance:
+11.22%
6M Performance:
+7.83%
1Y Performance:
+138.77%
1-Day Range:
$43.41
$46.40
1-Week Range:
$43.41
$51.56
52-Week Range:
$16.38
$51.56
Sionna Therapeutics Inc Stock (SION) Company Profile
Name
Sionna Therapeutics Inc
Sector
Industry
Phone
617-819-2020
Address
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
45.70 | 2.06B | 0 | -85.57M | -72.14M | -1.9166 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Citizens | Mkt Outperform |
| Dec-01-25 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-04-25 | Initiated | Guggenheim | Buy |
| Mar-04-25 | Initiated | Stifel | Buy |
| Mar-04-25 | Initiated | TD Cowen | Buy |
View All
Sionna Therapeutics Inc Stock (SION) Latest News
Sionna Therapeutics Slides as Lofty Valuation Deflates - TipRanks
Sionna Therapeutics Inc. (SION) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
SION Jumps As Sionna Therapeutics Stock Extends Breakout - StocksToTrade
SION Jumps As Sionna Therapeutics Draws Trader Attention - StocksToTrade
Sionna Therapeutics (SION) Sees 9.2% Surge in Stock Price - GuruFocus
Sionna Therapeutics stock hits all-time high at 48.66 USD - Investing.com
Sionna Therapeutics stock hits all-time high at 48.66 USD By Investing.com - Investing.com South Africa
Sionna Therapeutics Surges As CF Trial Data Loom - TipRanks
Orbimed Advisors LLC Reduces Stake in Sionna Therapeutics Inc - GuruFocus
Sionna Therapeutics, Inc. Common Stock (SION) Stock Price Today: $42.59 - Gotrade
Wedbush initiates coverage of Sionna Therapeutics (SION) with outperform recommendation - MSN
Sionna Therapeutics(SION.US) Director Sells US$3.85 Million in Common Stock - Moomoo
Form 4 Sionna Therapeutics Inc For: 9 July By Investing.com - Investing.com Nigeria
OrbiMed Advisors, Sionna director, sells $3.85 million in stock - Investing.com UK
Sionna Therapeutics director Peter Thompson sells $3.85m in stock - Investing.com
Sionna Therapeutics Insider Sold Shares Worth $3,854,281, According to a Recent SEC Filing - Moomoo
Sionna Therapeutics director Peter Thompson sells $3.85m in stock By Investing.com - Investing.com Canada
Sionna Therapeutics CLO Jennifer Fitzpatrick sells $446k in stock - Investing.com
Sionna Therapeutics CLO Jennifer Fitzpatrick sells $446k in stock By Investing.com - Investing.com Nigeria
Form 4 Sionna Therapeutics Inc For: 7 July By Investing.com - Investing.com Nigeria
Sionna Therapeutics (SION) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Is Sionna Therapeutics (SION) Undervalued Or Already Priced In As Index Changes Draw Focus? - simplywall.st
ETFs Investing in Sionna Therapeutics, Inc. Stocks - TradingView
SIONSionna Therapeutics Inc Options - Finviz
Form 4 Sionna Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Sionna Therapeutics director Thompson sells $5.27m in stock By Investing.com - Investing.com South Africa
Sionna Therapeutics director Thompson sells $5.27m in stock - Investing.com
Sionna Therapeutics Inc. (SION) Q1 2026 Earnings: Clinical-Stage Biotech Misses EPS Estimates Amid No RevenueROE Trend Analysis - dars.gov.et
Enterprise value to EBITDA forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Enterprise value to EBIT forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Enterprise value to revenue forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Price to earnings forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Price to sales forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Sionna Therapeutics: NBD1 Stabilization Could Redefine Cystic Fibrosis Treatment (SION) - Seeking Alpha
Sionna Therapeutics, Inc.(NasdaqGM: SION) dropped from Russell 3000E Index - marketscreener.com
Sionna Therapeutics, Inc.(NasdaqGM: SION) dropped from Russell Microcap Index - marketscreener.com
Sionna Therapeutics, Inc.(NasdaqGM:SION) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Sionna Therapeutics, Inc. Actuals & Estimates (NASDAQ:SION) - TradingView
SION Forecast — Price Target — Prediction for 2027 - TradingView
JonesTrading Maintains Sionna Therapeutics(SION.US) With Buy Rating, Maintains Target Price $63 - Moomoo
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Sionna Therapeutics, Inc. (SION) and Crescent Biopharma (CBIO) - The Globe and Mail
Citizens reiterates Sionna Therapeutics stock rating ahead of summer data By Investing.com - Investing.com Nigeria
Guggenheim Maintains Sionna Therapeutics(SION.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Sionna Therapeutics: Buy Rating Reiterated on NBD1-Focused CF Strategy; $60 Price Target Maintained - TipRanks
Sionna Stockholders Reelect Directors, Ratify Deloitte as Auditor - The Globe and Mail
LifeSci Capital Maintains Sionna Therapeutics(SION.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Sionna Therapeutics Surges 5.7%: Testing Key Resistance at $38.57Technical Analysis Picks - dars.gov.et
Sionna Therapeutics Inc Stock (SION) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sionna Therapeutics Inc Stock (SION) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Jul 07 '26 |
Sale |
44.86 |
85,918 |
3,854,281 |
2,469,959 |
| Fitzpatrick Jennifer | Chief Legal Officer |
Jul 06 '26 |
Option Exercise |
6.11 |
10,250 |
62,628 |
10,250 |
| Fitzpatrick Jennifer | Chief Legal Officer |
Jul 06 '26 |
Sale |
43.60 |
10,250 |
446,862 |
0 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):